ISS X: Exploring the Science of Maintenance Therapy for Advanced Ovarian Cancer: Understanding Homologous Recombination Deficiency and Novel Targeted Strategies

MTCC: 701

This symposium is supported by AstraZeneca.

Michael Birrer, MD, PhD, University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, Little Rock, AR

This program highlights the risk of recurrence in patients with advanced ovarian cancer and focuses on molecular pathways involved in tumorigenesis, including biomarkers of DNA-damage repair.